Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016

Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016
Published Jun 28, 2016
121 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV-F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- The report reviews Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV-F Protein)
- I

  
Source:
Document ID
GMDHC0161TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Overview111
Therapeutics Development123
  Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Stage of Development121
  Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Therapy Area131
  Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Indication141
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Companies174
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Products under Development by Universities/Institutes212
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Therapeutics Assessment236
  Assessment by Monotherapy/Combination Products231
  Assessment by Mechanism of Action241
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Companies Involved in Therapeutics Development2924
  Ablynx NV291
  Agilvax, Inc.301
  Aridis Pharmaceuticals LLC311
  Bavarian Nordic A/S321
  Celltrion, Inc.331
  Emergent BioSolutions Inc.341
  F. Hoffmann-La Roche Ltd.351
  Gene Techno Science Co., Ltd.361
  GenVec, Inc.371
  Gilead Sciences, Inc.381
  GlaxoSmithKline Plc391
  iBio, Inc.401
  Johnson &Johnson411
  mAbxience S.A.421
  MedImmune, LLC431
  Medivir AB441
  Mucosis B.V.451
  Navigen Pharmaceuticals, Inc.461
  Novavax, Inc.471
  Regeneron Pharmaceuticals, Inc.481
  Takeda Pharmaceutical Company Limited491
  The International Biotechnology Center (IBC) Generium501
  Vaxart, Inc.511
  VLP Biotech, Inc.521
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Drug Profiles5354
  (human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine Drug Profile531
  (influenza (virus like particle) + respiratory syncytial virus) vaccine Drug Profile541
  AK-0529 Drug Profile551
  ALX-0171 Drug Profile563
  AR-201 Drug Profile591
  GNR-007 Drug Profile601
  GV-2311 Drug Profile612
  JNJ-61187165AAA Drug Profile631
  JNJ-61187191AAA Drug Profile641
  MEDI-7510 Drug Profile652
  MEDI-8897 Drug Profile671
  Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections Drug Profile681
  Monoclonal Antibody to Inhibit RSV-G and RSV-F for RSV Infections Drug Profile691
  MVA-RSV Drug Profile701
  palivizumab biosimilar Drug Profile711
  palivizumab biosimilar Drug Profile721
  palivizumab biosimilar Drug Profile731
  palivizumab biosimilar Drug Profile741
  palivizumab biosimilar Drug Profile751
  presatovir Drug Profile762
  respiratory syncytial virus (virus like particle) vaccine Drug Profile781
  respiratory syncytial virus (virus like particle) vaccine Drug Profile791
  respiratory syncytial virus (virus like particle) vaccines Drug Profile801
  respiratory syncytial virus immune globulin (human) Drug Profile811
  respiratory syncytial virus vaccine Drug Profile821
  respiratory syncytial virus vaccine Drug Profile8310
  respiratory syncytial virus vaccine Drug Profile931
  respiratory syncytial virus vaccine Drug Profile941
  respiratory syncytial virus vaccine Drug Profile951
  respiratory syncytial virus vaccine Drug Profile961
  respiratory syncytial virus vaccine Drug Profile971
  respiratory syncytial virus vaccine Drug Profile981
  respiratory syncytial virus vaccine Drug Profile991
  RSV-001 Drug Profile1001
  RV-521 Drug Profile1011
  Small Molecules to Inhibit Respiratory Syncytial Virus Fusion Protein for RSV Infections Drug Profile1021
  suptavumab Drug Profile1031
  SynGEM Drug Profile1042
  Synthetic Peptides to Inhibit RSV-F Protein for RSV Infection Drug Profile1061
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Dormant Projects1071
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Discontinued Products1081
Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) Featured News &Press Releases10911
  Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program1091
  May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults1101
  May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations1111
  May 03, 2016: Ablynx reports positive top line results for its inhaled Anti-RSV Nanobody (ALX-0171) in a phase I/IIa Study in infants hospitalised with a RSV infection1112
  Mar 09, 2016: First consortium of local manufacturers to make affordable biosimilars available for low income countries1131
  Mar 04, 2016: Immune Design s GLAAS Platform Shown to Modulate the Allergic Immune Response1131
  Jan 20, 2016: Mucosis Secures 3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London1141
  Dec 21, 2015: Novavax Appoints Mark Twyman Vice President Marketing1151
  Dec 17, 2015: Ablynx Completes Enrolment Of The First-In-Infant Phase I/IIa Safety Study With Its Anti-RSV Nanobody And Extends The Trial For Younger Infants1151
  Dec 14, 2015: Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults1161
  Dec 03, 2015: Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization1161
  Nov 19, 2015: Vaxart Presents Positive Preclinical Data for Oral RSV Vaccine at RSV Vaccines for the World Conference1171
  Nov 16, 2015: Novavax to Make Multiple Presentations at RSV Vaccines for the World1181
  Nov 09, 2015: Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults1181
  Oct 29, 2015: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS Discovery Platform1191
Appendix1202
  Methodology1201
  Coverage1201
  Secondary Research1201
  Primary Research1201
  Expert Panel Validation1201
  Contact Us1201
  Disclaimer1211

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Respiratory-Syncytial-Virus-Fusion-Protein-RSV-F-Protein-Pipeline-Review-H1-2016-2088-16056>
  
APA:
Global Markets Direct - Market Research. (2016). Respiratory Syncytial Virus Fusion Protein (RSV-F Protein) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Respiratory-Syncytial-Virus-Fusion-Protein-RSV-F-Protein-Pipeline-Review-H1-2016-2088-16056>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.